|

Neratinib Maleate Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • National Cancer Institute (NCI)3

Indications

  • Cancer3
  • Recurrent Malignant Female Reproductive System Neoplasm2
  • Malignant Female Reproductive System Neoplasm2
  • Unresectable Malignant Solid Neoplasm2
  • Recurrent Malignant Solid Neoplasm2

Birmingham, Alabama2 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California1 trial

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

City of Hope Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.